Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 1/2013

01-02-2013 | Case Report

Severe EBV hepatitis treated with valganciclovir

Authors: R. Pisapia, A. Mariano, A. Rianda, A. Testa, A. Oliva, L. Vincenzi

Published in: Infection | Issue 1/2013

Login to get access

Abstract

We describe the case of an 18-year-old immunocompetent male patient with severe hepatitis during primary Epstein–Barr virus infection, treated with oral valganciclovir. During the initial therapy with corticosteroids, the patient’s clinical condition and liver function worsened, so we decided to add oral valganciclovir for its good bio-availability and previous encouraging experiences in different clinical settings, with rapid resolution of the symptoms.
Literature
1.
2.
Burgio GR, Monafo V. Infectious mononucleosis fifty years after the discovery of the Paul–Bunnell test. Infection. 1983;11:1–5.PubMedCrossRef
3.
Kimura H, Nagasaka T, Hoshino Y, Hayashi N, Tanaka N, Xu JL, et al. Severe hepatitis caused by Epstein–Barr virus without infection of hepatocytes. Hum Path. 2001;32:757–62.PubMedCrossRef
4.
Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein–Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg. 1998;4:469–76.PubMedCrossRef
5.
Ader F, Chatellier D, Le Berre R, Morand P, Fourrier F. Fulminant Epstein–Barr virus (EBV) hepatitis in a young immunocompetent subject. Med Mal Infect. 2006;36:396–8.PubMedCrossRef
6.
Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49:151–7.PubMedCrossRef
7.
Markin RS. Manifestations of Epstein–Barr virus-associated disorders in liver. Liver. 1994;14:1–13.PubMedCrossRef
8.
Drebber U, Kasper HU, Krupacz J, Haferkamp K, Kern MA, Steffen HM, et al. The role of Epstein–Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879–85.PubMedCrossRef
9.
10.
Hara S, Hoshino Y, Naitou T, Nagano K, Iwai M, Suzuki K, et al. Association of virus infected-T cell in severe hepatitis caused by primary Epstein–Barr virus infection. J Clin Virol. 2006;35:250–6.PubMedCrossRef
11.
Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, Montoya JG. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 and Epstein–Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol. 2006;37:S33–8.PubMedCrossRef
12.
Venturi C, Bueno J, Gavalda J, Tórtola T, Pou L, Medina A, et al. Impact of valganciclovir on Epstein–Barr virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant Proc. 2009;41:1038–40.PubMedCrossRef
13.
Adams LA, Deboer B, Jeffrey G, Marley R, Garas G. Ganciclovir and the treatment of Epstein–Barr virus hepatitis. J Gastroenterol Hepatol. 2006;21:1758–60.PubMedCrossRef
14.
15.
Hoshino Y, Nishikawa K, Ito Y, Kuzushima K, Kimura H. Kinetics of Epstein–Barr virus load and virus-specific CD8+ T cells in acute infectious mononucleosis. J Clin Virol. 2011;50:244–6.PubMedCrossRef
Metadata
Title
Severe EBV hepatitis treated with valganciclovir
Authors
R. Pisapia
A. Mariano
A. Rianda
A. Testa
A. Oliva
L. Vincenzi
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Infection / Issue 1/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0303-0

Other articles of this Issue 1/2013

Infection 1/2013 Go to the issue

Brief Report

De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli

Clinical and Epidemiological Study

Infection control: point prevalence study versus incidence study in Polish long-term care facilities in 2009–2010 in the Małopolska Region

Brief Report

Why is antimicrobial de-escalation under-prescribed for urinary tract infections?

Correspondence

Clinical significance of infections caused by plasmid-mediated AmpC β-lactamases and extended-spectrum β-lactamase-producing Escherichia coli

Images in Infection

Kaposi’s sarcoma symmetric mucosal lesions

Clinical and Epidemiological Study

Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits